GLUD1 inhibits hepatocellular carcinoma progression via ROS-mediated p38/JNK MAPK pathway activation and mitochondrial apoptosis
Discover Oncology · 12.01.2024 · 15 (1)
DOI: 10.1007/s12672-024-00860-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Discover Oncology, online erschienen am 12.01.2024. Verfasst von Qianwei Zhao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450052, China. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Key Scientific and Technological Project of Henan Province, the Natural Science Foundation of Henan, the Project of Basic Research Fund of Henan Institute of Medical and Pharmacological Sciences.
Abstract (Originalsprache)
Glutamate dehydrogenase 1 (GLUD1) is an important enzyme in glutamine metabolism. Previously, we found GLUD1 was down-regulated in tumor tissues of hepatocellular carcinoma (HCC) patients by proteomics study. To explore its role in the progression of HCC, the expressional level of GLUD1 was firstly examined and presented as that both the protein and mRNA levels were down-regulated in tumor tissues compared to the normal liver tissues. GLUD1 overexpression significantly inhibited HCC cells proliferation, migration, invasion and tumor growth both in vitro and in vivo, while GLUD1 knocking-down promoted HCC progression. Metabolomics study of GLUD1 overexpressing and control HCC cells showed that 129 differentially expressed metabolites were identified, which mainly included amino acids, bases, and phospholipids. Moreover, metabolites in mitochondrial oxidative phosphorylation system (OXPHOS) were differentially expressed in GLUD1 overexpressing cells. Mechanistic studies showed that GLUD1 overexpression enhanced mitochondrial respiration activity and reactive oxygen species (ROS) production. Excessive ROS lead to mitochondrial apoptosis that was characterized by increased expression levels of p53, Cytochrome C, Bax, Caspase 3 and decreased expression level of Bcl-2. Furthermore, we found that the p38/JNK MAPK pathway was activated in GLUD1 overexpressing cells. N-acetylcysteine (NAC) treatment eliminated cellular ROS and blocked p38/JNK MAPK pathway activation, as well as cell apoptosis induced by GLUD1 overexpression. Taken together, our findings suggest that GLUD1 inhibits HCC progression through regulating cellular metabolism and oxidative stress state, and provide that ROS generation and p38/JNK MAPK pathway activation as promising methods for HCC treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450052, China.
- School of Basic Medical Sciences, Academy of Medical Science, Zhengzhou University, Zhengzhou, 450052, China.
- BGI College, Zhengzhou University, Zhengzhou, 450052, China.
- Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450052, China. jianshang0210@zzu.edu.cn.
- Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450052, China. jtzhang@zzu.edu.cn.
- Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, 450052, China. jtzhang@zzu.edu.cn.
Förderung
- the Key Scientific and Technological Project of Henan Province
- the Natural Science Foundation of Henan
- the Project of Basic Research Fund of Henan Institute of Medical and Pharmacological Sciences
Zitieren
APA
Zhao, Q., Yu, M., Li, J., Guo, Y., Wang, Z., Hu, K., Xu, F., Liu, Y., Li, L., Wan, D., Zhao, Y., Shang, J., & Zhang, J. (2024). GLUD1 inhibits hepatocellular carcinoma progression via ROS-mediated p38/JNK MAPK pathway activation and mitochondrial apoptosis. Discover Oncology, 15(1). https://doi.org/10.1007/s12672-024-00860-1
Vancouver
Zhao Q, Yu M, Li J, Guo Y, Wang Z, Hu K, et al. GLUD1 inhibits hepatocellular carcinoma progression via ROS-mediated p38/JNK MAPK pathway activation and mitochondrial apoptosis. Discover Oncology. 2024;15(1). doi:10.1007/s12672-024-00860-1
BibTeX
@article{Zhao2024,
author = {Zhao, Qianwei and Yu, Mengdan and Li, Jinxia and Guo, Yaoyu and Wang, Zexuan and Hu, Kefei and Xu, Fang and Liu, Yixian and Li, Lili and Wan, Didi and Zhao, Ying and Shang, Jian and Zhang, Jintao},
title = {GLUD1 inhibits hepatocellular carcinoma progression via ROS-mediated p38/JNK MAPK pathway activation and mitochondrial apoptosis},
journal = {Discover Oncology},
year = {2024},
volume = {15},
number = {1},
doi = {10.1007/s12672-024-00860-1}
}
EUVIMED